Can a new drug combo shrink liver tumors?
NCT ID NCT07761286
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This study tests whether adding an experimental drug called SYS6090 to standard cancer treatments can safely and effectively shrink tumors in people with advanced hepatocellular carcinoma, the most common type of liver cancer. Participants will receive SYS6090 combined with bevacizumab, with or without another experimental drug, or a standard combination of bevacizumab and sintilimab. The trial aims to find the best dose and measure how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SYS6090 injection combined with bevacizumab, with or without SYS6043, compared to bevacizumab plus sintilimab
- What this could lead to
- If successful, this combination could offer a new treatment option that shrinks tumors and improves outcomes for people with advanced liver cancer.
- What could go wrong
- This is an early-stage trial, so safety and effectiveness are not yet proven. The combination may cause side effects or may not work better than existing therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Harbin medical university Cancer Hospital
Harbin, Heilongjiang, 150000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ancient herbal mix could boost liver health in advanced cancer
- Double immune attack: new drug combo takes on advanced liver cancer
- Breathing pure oxygen during an MRI may reveal whether liver cancer treatment is working
- Radiation and drug combo shows promise for tough liver cancers
- New immunotherapy combo aims to stop liver cancer return after surgery
- New triple therapy aims to stop liver cancer from coming back